UNSPSC 51294508: Litoxetine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9980ST005G. European Medicines Agency schedules Litoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08536MIG. Litoxetine generally arises in the molecular formula C16H19NO. The term LITOXETINE is an International Non-Proprietary Name or INN. LITOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule litoxetine under HS 29333999 and SITC 51574. As of Q4 2014, LITOXETINE remains the US FDA Preferred Term for this commodity. Litoxetine bears US NLM identifiers UMLS ID C0165077 and NCI Concept Code C66021. SMILES: O(C1CCNCC1)Cc1cc2c(cc1)cccc2.

UNSPSC 51294508 Litoxetine is a Commodity code that does not reflect the actual pharmaceutical procurement activity currently posted under it by state and local government bodies. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are litoxetine-specific products or manufacturers. State and local health departments and pharmacy benefit programs are using this code to solicit broad pharmaceutical supply agreements, therapeutic pharmacy initiatives, and over-the-counter product procurement rather than purchases of a single active pharmaceutical ingredient. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance covering Minnesota, Oregon, and other participating jurisdictions).

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023, later posted June 30, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to assess vendor capacity for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, released an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026. The code shows little relevant activity aligned to its stated commodity name and appears misapplied to broader pharmaceutical supply and management solicitations.